Merck: terminates two phase III trials on Keytruda
(CercleFinance.com) - Merck has announced the termination of two Phase 3 clinical trials involving Keytruda.
The first trial, KEYNOTE-867, evaluated the efficacy of Keytruda in combination with radiotherapy for non-small cell lung cancer. It was stopped because it showed no significant improvement in survival compared with placebo, and was associated with more serious adverse events.
Similarly, the KEYNOTE-630 trial, which tested Keytruda as an adjuvant treatment for cutaneous squamous cell carcinoma, was stopped for 'futility'.
Merck has informed investigators and patients, and the results will be shared with the scientific community.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The first trial, KEYNOTE-867, evaluated the efficacy of Keytruda in combination with radiotherapy for non-small cell lung cancer. It was stopped because it showed no significant improvement in survival compared with placebo, and was associated with more serious adverse events.
Similarly, the KEYNOTE-630 trial, which tested Keytruda as an adjuvant treatment for cutaneous squamous cell carcinoma, was stopped for 'futility'.
Merck has informed investigators and patients, and the results will be shared with the scientific community.
Copyright (c) 2024 CercleFinance.com. All rights reserved.